Skip to content
value.today

Centogene: peers

Change the peers

Centogene beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Centogene, NanoRepro AG, Mdxhealth SA, Predilife S.A., Biocartis Group NV, Renalytix plc: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Centogene, NanoRepro AG, Mdxhealth SA, Predilife S.A., Biocartis Group NV, OneMedNet Corp, Star Equity Holdings, Inc., Renalytix plc side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCentogenebase
39K.F · 🇩🇪 DE
Percentile in Healthcare
Percentile in Germany
NanoRepro AG
NN6.DE · 🇩🇪 DE
Percentile in Healthcare
Percentile in Germany
Mdxhealth SA
MDXH · 🇧🇪 BE
Percentile in Healthcare
Percentile in Belgium
Predilife S.A.
ALPRE.PA · 🇫🇷 FR
Percentile in Healthcare
Percentile in France
Biocartis Group NV
8XB.F · 🇧🇪 BE
Percentile in Healthcare
Percentile in Belgium
OneMedNet Corp
ONMD · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
Star Equity Holdings, Inc.
STRR · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Renalytix plc
RNLXY · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
Group median
Size
Market cap (Better neither way: ranked highest first)$28 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8$28 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8$42 MAug 1, 2026 · Market data1st of 8$23 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8$37 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8$27 MOct 30, 2026 · Market data6th of 8$37 MOct 15, 2026 · Market data2nd of 8$21 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8$28 M8 ranked
Revenue (Better neither way: ranked highest first)————$108 MFY2025 · SEC2nd of 5——$51 MFY2023 · ESEF3rd of 5$1 MFY2025 · SEC5th of 5$172 MFY2025 · SEC1st of 5$2 MFY2024 · SEC4th of 5$51 M5 ranked
Net income (Higher is better)————$-34 MFY2025 · SEC5th of 5——$20 MFY2023 · ESEF1st of 5$-3 MFY2025 · SEC2nd of 5$-6 MFY2025 · SEC3rd of 5$-33 MFY2024 · SEC4th of 5$-6 M5 ranked
Employees (Better neither way: ranked highest first)————364December 31, 2025 · Profile2nd of 2——————1,200December 31, 2025 · Profile1st of 2——7822 ranked
Growth
Revenue growth (Higher is better)————————+19.8%FY2025 · SEC3rd of 468th86th————————+112.5%FY2025 · SEC1st of 493rd99th+22.9%FY2025 · SEC2nd of 472nd81st-32.6%FY2024 · SEC4th of 47th1st+21.4%4 ranked
Revenue growth, 3 years a year (Higher is better)————————+42.8%FY2025 · SEC1st of 487th—————————+5.8%FY2025 · SEC3rd of 444th50th-5.0%FY2025 · SEC4th of 417th18th+15.4%FY2024 · SEC2nd of 465th78th+10.6%4 ranked
Margins and returns
Gross margin (Higher is better)————————64.5%FY2025 · SEC1st of 459th98th————————-36.8%FY2025 · SEC4th of 41st1st46.4%FY2025 · SEC2nd of 432nd59th7.0%FY2024 · SEC3rd of 44th5th26.7%4 ranked
Operating margin (Higher is better)————————-13.4%FY2025 · SEC2nd of 345th10th————————-711.0%FY2025 · SEC3rd of 33rd0th-2.1%FY2025 · SEC1st of 355th36th————-13.4%3 ranked
Net margin (Higher is better)————————-31.1%FY2025 · SEC2nd of 338th7th————————-205.9%FY2025 · SEC3rd of 315th2nd-3.4%FY2025 · SEC1st of 356th36th————-31.1%3 ranked
Free cash flow margin (Higher is better)————————-3.1%FY2025 · SEC1st of 347th25th————————-552.2%FY2025 · SEC3rd of 36th1st-5.2%FY2025 · SEC2nd of 345th25th————-5.2%3 ranked
Return on equity (Higher is better)————————————————————————-11.2%FY2025 · SEConly one with it66th33rd————-11.2%—
Valuation
Price to sales (Better neither way: ranked highest first)————————0.4×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————11.8×price Oct 30, 2026 · Market data1st of 276th97th0.2×price Oct 15, 2026 · Market data2nd of 22nd4th————6.0×2 ranked
Price to book (Better neither way: ranked highest first)————————————————————————0.6×price Oct 15, 2026 · Market dataonly one with it8th8th————0.6×—
Free cash flow yield (Higher is better)————————-8.0%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————-27.7%price Oct 30, 2026 · Market data2nd of 227th11th-24.2%price Oct 15, 2026 · Market data1st of 230th13th————-26.0%2 ranked
Financial strength
Debt to equity (Lower is better)————————————————————————0.1×FY2025 · SEConly one with it19th14th————0.1×—
Interest cover (Higher is better)————————————————————-138.1×FY2025 · SEConly one with it11th3rd————————-138.1×—
Piotroski F-score (Higher is better)——————————6 of 9FY2025 · SEC1st of 21 of 9FY2025 · SEC2nd of 2——3.5 of 92 ranked
Scorecard
Scorecard (Higher is better)————5 of 11FY2025 · Scorecard1st of 4————4 of 19FY2025 · Scorecard4th of 48 of 24FY2025 · Scorecard2nd of 43 of 10FY2024 · Scorecard3rd of 432% passed4 ranked
Valuation checks (Higher is better)——————————0 of 5FY2025 · Scorecard2nd of 22 of 5FY2025 · Scorecard1st of 2——20% passed2 ranked
Growth checks (Higher is better)————4 of 6FY2025 · Scorecard2nd of 4————3 of 4FY2025 · Scorecard1st of 41 of 6FY2025 · Scorecard4th of 43 of 5FY2024 · Scorecard3rd of 463% passed4 ranked
Profitability checks (Higher is better)————1 of 4FY2025 · Scorecard1st of 4————0 of 4FY2025 · Scorecard3rd of 41 of 5FY2025 · Scorecard2nd of 40 of 2FY2024 · Scorecard3rd of 410% passed4 ranked
Financial health checks (Higher is better)————0 of 1FY2025 · Scorecard3rd of 4————1 of 5FY2025 · Scorecard2nd of 43 of 5FY2025 · Scorecard1st of 40 of 2FY2024 · Scorecard3rd of 410% passed4 ranked
Shareholder returns checks (Higher is better)——————————0 of 1FY2025 · Scorecard2nd of 31 of 3FY2025 · Scorecard1st of 30 of 1FY2024 · Scorecard2nd of 30% passed3 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)————44.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3————2.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 325.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 3——25.0%3 ranked
Institutions holding (Better neither way: ranked highest first)————242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3————132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 3242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3——243 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————-31.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 2——————+0.8 pp2026-Q2 against 2026-Q1 · 13F1st of 2——-15.4 pp2 ranked
Dividends
Shareholder yield (Higher is better)————————————————————————7.1%FY2025 · SEConly one with it84th80th————7.1%—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Centogene: How market caps are worked out; NanoRepro AG: How market caps are worked out; Mdxhealth SA: How market caps are worked out; Predilife S.A.: How market caps are worked out; Biocartis Group NV: How market caps are worked out; OneMedNet Corp: How market caps are worked out; Star Equity Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Renalytix plc: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Centogene———
NanoRepro AG———
Mdxhealth SA-13.4%FY2025
45th percentile in Healthcaremedian -7.8%, 678 companies
10th percentile in Belgiummedian 7.5%, 36 companies
Predilife S.A.———
Biocartis Group NV———
OneMedNet Corp-711.0%FY2025
3rd percentile in Healthcaremedian -7.8%, 678 companies
0th percentile in UKmedian 8.5%, 313 companies
Star Equity Holdings, Inc.-2.1%FY2025
55th percentile in Healthcaremedian -7.8%, 678 companies
36th percentile in USAmedian 3.4%, 2,607 companies
Renalytix plc———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$233 M$467 M$700 M$934 M20102012201420162018202020222024Mdxhealth SA $108 MBiocartis Group NV $51 MOneMedNet Corp $1 MStar Equity Holdings, Inc. $172 MRenalytix plc $2 M

Rank in the group

1st2nd3rd4th5th2019202020212022202320242025Mdxhealth SA: 2nd of 2 in 2019Mdxhealth SA: 2nd of 2 in 2020Mdxhealth SA: 2nd of 3 in 2021Mdxhealth SA: 3rd of 5 in 2022Mdxhealth SA: 2nd of 5 in 2023Mdxhealth SA: 2nd of 4 in 2024Mdxhealth SA: 2nd of 3 in 2025Mdxhealth SABiocartis Group NV: 2nd of 5 in 2022Biocartis Group NV: 3rd of 5 in 2023Biocartis Group NVOneMedNet Corp: 5th of 5 in 2022OneMedNet Corp: 5th of 5 in 2023OneMedNet Corp: 4th of 4 in 2024OneMedNet Corp: 3rd of 3 in 2025OneMedNet CorpStar Equity Holdings, Inc.: 1st of 2 in 2019Star Equity Holdings, Inc.: 1st of 2 in 2020Star Equity Holdings, Inc.: 1st of 3 in 2021Star Equity Holdings, Inc.: 1st of 5 in 2022Star Equity Holdings, Inc.: 1st of 5 in 2023Star Equity Holdings, Inc.: 1st of 4 in 2024Star Equity Holdings, Inc.: 1st of 3 in 2025Star Equity Holdings, Inc.Renalytix plc: 3rd of 3 in 2021Renalytix plc: 4th of 5 in 2022Renalytix plc: 4th of 5 in 2023Renalytix plc: 3rd of 4 in 2024Renalytix plc
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCentogeneNanoRepro AGMdxhealth SAPredilife S.A.Biocartis Group NVOneMedNet CorpStar Equity Holdings, Inc.Renalytix plc
2025——$108 MSEC2nd——$1 MSEC3rd$172 MSEC1st—
2024——$90 MSEC2nd——$1 MSEC4th$140 MSEC1st$2 MSEC3rd
2023——$70 MSEC2nd—$51 MESEF3rd$1 MSEC5th$161 MSEC1st$3 MSEC4th
2022——$37 MSEC3rd—$60 MESEF2nd$1 MSEC5th$201 MSEC1st$3 MSEC4th
2021——$22 MSEC2nd———$169 MSEC1st$1 MSEC3rd
2020——$18 MSEC2nd———$101 MSEC1st—
2019——$12 MSEC2nd———$94 MSEC1st—
2018——————$67 MSEC—
2017——————$457 MSEC—
2016——————$423 MSEC—
2015——————$463 MSEC—
2014——————$581 MSEC—

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Centogene#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • NanoRepro AGNN6.DE · 🇩🇪 Germany
    Same industry: Diagnostics and Research · Similar size: $28 M market cap against $28 M · Same country: Germany
    Market cap $28 M (last known, Jan 5, 2024)
    95 of 100 (industry or sector 50 + size 30 + country 15)
    In the group
  • Mdxhealth SAMDXH · 🇧🇪 Belgium
    Same industry: Diagnostics and Research · Similar size: $42 M market cap against $28 M · Same region: Western Europe · Ratios of the last two fiscal years on file
    Market cap $42 M (Aug 1, 2026) · revenue $108 M (year to December 2025)
    89 of 100 (industry or sector 50 + size 27 + country 7 + figures on file 5)
    In the group
  • Predilife S.A.ALPRE.PA · 🇫🇷 France
    Same industry: Diagnostics and Research · Similar size: $23 M market cap against $28 M · Same region: Western Europe
    Market cap $23 M (last known, Jan 5, 2024)
    86 of 100 (industry or sector 50 + size 29 + country 7)
    In the group
  • Biocartis Group NV8XB.F · 🇧🇪 Belgium
    Same industry: Diagnostics and Research · Similar size: $37 M market cap against $28 M · Same region: Western Europe
    Market cap $37 M (last known, Jul 30, 2023) · revenue $51 M (year to December 2023)
    85 of 100 (industry or sector 50 + size 28 + country 7)
    In the group
  • OneMedNet CorpONMD · 🇬🇧 UK
    Same industry: Diagnostics and Research · Similar size: $27 M market cap against $28 M · Ratios of the last two fiscal years on file
    Market cap $27 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Star Equity Holdings, Inc.STRR · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $37 M market cap against $28 M · Ratios of the last two fiscal years on file
    Market cap $37 M (Oct 15, 2026) · revenue $172 M (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    In the group
  • Renalytix plcRNLXY · 🇬🇧 UK
    Same industry: Diagnostics and Research · Similar size: $21 M market cap against $28 M · Ratios of the last two fiscal years on file
    Market cap $21 M (last known, Jan 5, 2024) · revenue $2 M (year to June 2024)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    In the group
  • Precipio, Inc.PRPO · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $38 M market cap against $28 M · Ratios of the last two fiscal years on file
    Market cap $38 M (Oct 22, 2026) · revenue $53 M (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Novacyt S.A.ALNOV.PA · 🇫🇷 France
    Same industry: Diagnostics and Research · Similar size: $55 M market cap against $28 M · Same region: Western Europe
    Market cap $55 M (last known, Jan 5, 2024) · revenue $385 M
    83 of 100 (industry or sector 50 + size 26 + country 7)
    + Add
  • DarioHealth Corp.DRIO · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $42 M market cap against $28 M · Ratios of the last two fiscal years on file
    Market cap $42 M (Oct 22, 2026) · revenue $22 M (year to December 2025)
    82 of 100 (industry or sector 50 + size 27 + figures on file 5)
    + Add
  • Epigenomics AGEPGNF · 🇩🇪 Germany
    Same industry: Diagnostics and Research · 7.0× smaller by market cap · Same country: Germany
    Market cap $4 M (last known, Jul 30, 2023)
    82 of 100 (industry or sector 50 + size 17 + country 15)
    + Add
  • Bionano Genomics, Inc.BNGO · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $17 M market cap against $28 M · Ratios of the last two fiscal years on file
    Market cap $17 M (Oct 30, 2026) · revenue $29 M (year to December 2025)
    82 of 100 (industry or sector 50 + size 27 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.